How Cannabis MSOs Consolidation Affects Patient Access and Pricing
Cannabis MSOs consolidation impact is reshaping patient access and pricing in medical cannabis markets. This trend influences supply chain stability and product consistency. Understanding these effects is crucial for clinicians and patients alike.
Meet Jasmine Johnson, The Founder Of Florida’s First Black-Woman‑Owned Cannabis Ecosystem
Diversity in cannabis business ownership is crucial for improving patient access and healthcare equity. Jasmine Johnson's pioneering role highlights the impact of underrepresented entrepreneurs. This focus on diversity supports culturally competent…
President’s Update: Scope of Practice, Medicinal Cannabis, Ahpra News and More
This update covers medicinal cannabis prescribing Australia and recent regulatory changes impacting clinical practice. Ahpra news and scope of practice revisions are central to these developments. Clinicians should monitor these updates to optimize…
Mississippi Lawmakers Approve Changes to Medical Cannabis Program – WAPT
Mississippi medical cannabis program modifications affect patient access and treatment options in a traditionally restrictive state. These changes influence qualifying conditions and physician recommendations. Monitoring these modifications is essential…
Mississippi House concurs with Senate on medical cannabis changes | Tippah News
✦ New CED Clinical Relevance #76Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. ⚒ Cannabis News | CED Clinic PolicyMississippiMedical CannabisLegislationPatient Access Why This Matters Legislative changes…
When Will Virginia’s Cannabis Marketplace Open?
Virginia cannabis marketplace timing is crucial for patient access to regulated cannabis products. The state is considering legislation to establish a regulated market. This timing affects availability of consistent, lab-tested cannabis medicines.
Americans Lighten Up About Marijuana While Judging Everything Else
Shifting public attitudes toward cannabis are reducing social stigma and encouraging more honest patient disclosure. This change impacts clinical decision-making around cannabis-based therapeutics. As acceptance grows, healthcare providers can better…
Cannabis and Anxiety Relief in Real-World Patients: A 45-Day Longitudinal Analysis
A 45-day longitudinal study tracked cannabis-use days anxiety relief in 416 medical cannabis patients. Cannabis-use days showed larger same-day reductions in anxiety compared to non-cannabis days. This real-world data highlights patient-reported benefits…
Tylenol and Autism: 7 Insights You Need Now
Tylenol has long been the go-to pain reliever during pregnancy, but a new wave of research questions its safety. This post unpacks the science, the panic, and the human stories behind the headlines on Tylenol and autism. The truth? It’s…
When Confidence Replaces Competence: A Rebuttal to WSJ’s Cannabis Coverage
Cherry-picking cannabis science distorts the truth and misleads public understanding. This article highlights the importance of the endocannabinoid system in cannabis research. It calls for evidence-based discussion over biased claims.
